Christopher Ryan Sullivan, Chief Financial Officer at Avalo Therapeutics, Inc. (AVTX), sold 72,725 shares at $19.85 ($1.5M) on 2026-08-17, disclosed to the SEC on 2026-08-19.
Scheduled sale ($1.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.85 | 37,945 | $753K | 51.9% |
| 2 | $19.94 | 3,749 | $75K | 5.2% |
| 3 | $20.05 | 31,031 | $622K | 42.9% |
| Total | $19.94 avg | 72,725 | $1.5M | 100% |
| Filing → |
| AVTX | SELL | 2026-05-11 | $449K | — | Filing → |
| AVTX | SELL | 2026-05-07 | $949K | — | Filing → |
| AVTX | SELL | 2026-05-01 | $223K | — | Filing → |